June 9, 2009
Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281

February 10, 2009
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, A Novel sEh Inhibitor to Treat Type 2 Diabetes

December 18 , 2008
Arete Therapeutics Reports Positive Phase I Data for AR9281

November 19, 2008
Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing

Arete Therapeutics Home Page